Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13354427 | 0.77 | CYP2A6 (0.38) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13086437 | 0.73 | CYP2A6 (0.39) | KDM4EALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6664965 | 0.72 | KDM4E (0.75) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL25584932 | 0.69 | PDE4A (0.38) | KDM4EALDH1A1CYP2A6 | |
| SCHEMBL558692 | 0.69 | PIM1 (0.38) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL11090930 | 0.69 | KDM4E (0.40) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL21764269 | 0.68 | CYP2A6 (0.48) | KDM4EALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL16505415 | 0.68 | KDM4E (0.44) | KDM4EALDH1A1CYP1A2CYP3A4HTR1A | |
| SCHEMBL17203651 | 0.68 | KDM4E (0.43) | KDM4EALDH1A1MAPTCYP2A6CDK2 | |
| SCHEMBL1963980 | 0.68 | KMT2A (0.49) | KDM4EALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458979-A | Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | 诺华股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-2152700-B1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| CN-101754965-A | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG | 2010-06-23 | — | — | CN | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152700-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Novartis Ag (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008144062-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | KDM4E 1776/4885ALDH1A1 623/4885MEN1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.